LEXICON PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
LXRX$1.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands)
| Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additional · Other | |||||||||
| Common Stock · Preferred Stock · Paid-In · Accumulated · Comprehensive · Treasury | |||||||||
| Shares | Par Value | Shares | Par Value | Capital | Deficit | Income (Loss) | Stock | Total | |
| Balance at December 31, 2022 | 189,214 | $189 | — | $— | $1,709,144 | $(1,589,720) | $(428) | $(2,061) | $117,124 |
| Issuance of equity-classified warrants | — | — | — | — | 307 | — | — | — | 307 |
| Stock-based compensation | — | — | — | — | 14,340 | — | — | — | 14,340 |
| Issuance of common stock, net of fees | 55,288 | 55 | — | — | 138,768 | — | — | — | 138,823 |
| Issuance of common stock under Equity Incentive Plans | 1,291 | 1 | — | — | (1) | — | — | — | — |
| Payments for tax withholding on share-based compensation vesting | — | — | — | — | — | — | — | (824) | (824) |
| Net loss | — | — | — | — | — | (177,119) | — | — | (177,119) |
| Unrealized gain on investments | — | — | — | — | — | — | 459 | — | 459 |
| Balance at December 31, 2023 | 245,793 | $245 | — | $— | $1,862,558 | $(1,766,839) | $31 | $(2,885) | $93,110 |
| Stock-based compensation | — | — | — | — | 13,499 | — | — | — | 13,499 |
| Issuance of preferred stock, net of fees | — | — | 2,304 | 23 | 241,299 | — | — | — | 241,322 |
| Issuance of common stock under Equity Incentive Plans | 2,020 | 3 | — | — | 61 | — | — | — | 64 |
| Payments for tax withholding on share-based compensation vesting | — | — | — | — | — | — | — | (1,730) | (1,730) |
| Conversion of preferred stock to common stock | 115,207 | 115 | (2,304) | (23) | (92) | — | — | — | — |
| Net loss | — | — | — | — | — | (200,403) | — | — | (200,403) |
| Unrealized gain on investments | — | — | — | — | — | — | 88 | — | 88 |
| Balance at December 31, 2024 | 363,020 | $363 | — | $— | $2,117,325 | $(1,967,242) | $119 | $(4,615) | $145,950 |
| Stock-based compensation | — | — | — | — | 12,517 | — | — | — | 12,517 |
| Issuance of common stock under Equity Incentive Plans | 2,828 | 3 | — | — | 70 | — | — | — | 73 |
| Payments for tax withholding on share-based compensation vesting | — | — | — | — | — | — | — | (572) | (572) |
| Net loss | — | — | — | — | — | (50,341) | — | — | (50,341) |
| Unrealized loss on investments | — | — | — | — | — | — | (89) | — | (89) |
| Balance at December 31, 2025 | 365,848 | $366 | — | $— | $2,129,912 | $(2,017,583) | $30 | $(5,187) | $107,538 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.